Clinically, many patients with malignant tumors are often at advanced stages once they are detected. Even for some tumor patients who can be operated, recurrence or metastasis often occurs after surgery. The use of new minimally invasive treatment for such patients can not only prolong the survival period, but also greatly improve the quality of life of patients. Among them, the combination of radioactive and chemical particles is the best combination of radioactive and chemical treatment for tumors, and its effect is better than one minimally invasive method alone. A large number of clinical cases have verified that this method is a safer method among various minimally invasive treatment methods, and it has fewer complications, wide indications and good efficacy. The principle of inter-tissue implantation of radioactive iodine particles is a kind of intra-tumor radiation therapy, in which radioactive element I releases g-rays and soft X-rays after inter-tissue decay. g-rays can break the single or double strands of tumor DNA through direct ionization, while soft X-rays can kill tumor cells by generating oxygen radicals through indirect ionization and inhibit the proliferation of tumor cells with short cell cycle and rapid growth. I particles have an effective radiation radius of only 1.7 cm, which only irradiate continuously locally in the tumor, while the surrounding normal tissues are almost unaffected, achieving the purpose of intensity modulation. Since the radioactive particles are evenly distributed in the tumor, it also achieves the purpose of conformal, and at the same time, the particles can move with the tumor at any time in the tumor, which achieves the purpose of following the target and reduces the complications to the lowest degree compared with the external radiotherapy. In addition, the first half-life of radioactive particle I is 59.6 days, during which the tumor can be completely killed, and the second half-life is about 180 days, and the particle I can also release part of the g-rays, so it can play a role in preventing tumor recurrence. The chemotherapeutic particles are slow-release fluorouracil for implantation, with a slow-release action time of about 21 days. For solid tumors. The concentration and duration of drug produced by a single implantation is approximately equivalent to dozens to hundreds of intravenous doses. The biggest problem of chemotherapy has been its systemic toxic reaction, that is, the anti-cancer drugs kill tumor cells and also produce similar destructive effects on the vital organs (such as liver and kidney) or systems (such as hematopoietic system) of the body, so that the body is forced to interrupt chemotherapy only when it is overwhelmed by obvious toxic side effects. The efficacy of chemotherapy depends mainly on the product of the concentration of the drug at the tumor site and the duration of action. The implantation of chemotherapeutic particles can achieve the purpose of local long-lasting chemotherapy, increase the local drug concentration and the duration of drug action, increase the killing effect on tumor tissues, and reduce the systemic toxic side effects. The combined application of radioactive and chemical particles can play the role of sensitization by combining radiotherapy and chemotherapy; radiotherapy is effective for eradicating local lesions, and chemotherapy is effective for killing subclinical lesions that are not irradiated by radiotherapy, and the two cooperate to add up the anti-tumor effects by acting on the same cell population or on different subpopulations of the same cell population. It is suitable for patients with tumors that cannot be surgically removed from various parts of the body, patients who need to preserve organ functions (such as tumors adjacent to or encircling blood vessels, nerves, or urinary tracts that cannot be surgically removed), metastatic tumors that have lost their surgical value, or patients who are unwilling to undergo surgical treatment due to too much risk and damage, elderly people with diabetes and heart disease, and patients who have recurrence after surgery or poor results of radiotherapy or chemotherapy.